Limits...
A decline of LAMP- 2 predicts ursodeoxycholic acid response in primary biliary cirrhosis.

Wang L, Guo GY, Wang JB, Zhou XM, Yang Q, Han ZY, Li Q, Zhang JW, Cai Y, Ren XL, Zhou X, Chen RR, Shi YQ, Han Y, Fan DM - Sci Rep (2015)

Bottom Line: We found that the basal serum LAMP-2 level was increased in PBC, especially in patients with stage III-IV (p = 0.010) or TBIL > 1 mg/dL (p = 0.014).Baseline serum LAMP-2 was higher in non-responders than that in responders, but the difference was statistically insignificant.However, after UDCA treatment, serum LAMP-2 level decreased prominently in the first 3 months, which was more obvious in responders.

View Article: PubMed Central - PubMed

Affiliation: Division of Hepatology, Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xian, 710032, Shaanxi Province, China.

ABSTRACT
Biochemical response to ursodeoxycholic acid (UDCA) in patients with primary biliary cirrhosis (PBC) is variable. We have previously reported that augmented expression of lysosome-associated membrane protein 2 (LAMP-2) was correlated with the severity of PBC. This study aimed to determine whether serum LAMP-2 could serve as a predictor of biochemical response to UDCA. The efficiency of serum LAMP-2 to predict biochemical response was assessed after 1 year of UDCA treatment in PBC patients by a retrospective analysis. We found that the basal serum LAMP-2 level was increased in PBC, especially in patients with stage III-IV (p = 0.010) or TBIL > 1 mg/dL (p = 0.014). Baseline serum LAMP-2 was higher in non-responders than that in responders, but the difference was statistically insignificant. However, after UDCA treatment, serum LAMP-2 level decreased prominently in the first 3 months, which was more obvious in responders. Further studies showed that the 35% decline of LAMP-2 after treatment for 3 months could be stated as an indicator of UDCA response with the sensitivity of 62.9% and specificity of 75.0% by Paris criteria. Meanwhile the specificity and sensitivity were identified as 63.5% and 64.1% by Barcelona criteria. Together, a decline in LAMP-2 might help to predict the response to UDCA.

No MeSH data available.


Related in: MedlinePlus

The changes of serum LAMP-2 levels in responders and non-responders after 1 year of UDCA treatment.(a, b) The prominent decline in LAMP-2 was noted in the third month in responders. (c, d) The changes of serum LAMP-2 levels in responders and non-responders. Each datum was normalized by dividing it by its corresponding baseline. The biochemical responses were evaluated by Paris Definitions (a and c) or by Barcelona Definitions (b and d). Data are expressed as mean SEM. *p<0.001 versus baseline.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4403591&req=5

f4: The changes of serum LAMP-2 levels in responders and non-responders after 1 year of UDCA treatment.(a, b) The prominent decline in LAMP-2 was noted in the third month in responders. (c, d) The changes of serum LAMP-2 levels in responders and non-responders. Each datum was normalized by dividing it by its corresponding baseline. The biochemical responses were evaluated by Paris Definitions (a and c) or by Barcelona Definitions (b and d). Data are expressed as mean SEM. *p<0.001 versus baseline.

Mentions: Under UDCA therapy, a prominent decline in serum LAMP-2 was noted in the third month in responders, and gradually decreased subsequently, with a maximum decrease observed at the sixth month (Figs. 4a and b, green; p<0.001). However, serum LAMP-2 was decreased slightly in non-responders (Figs. 4a and b, red), even with an elevation at 1 year (Fig. 4b). After 1 year of UDCA treatment, serum LAMP-2 was decreased by about 42% with Paris criteria, and 45% with Barcelona criteria in responders, while in non-responders it was decreased by about 2% with Paris criteria and 10% with Barcelona criteria. The changes of serum LAMP-2 after 1 year of UDCA therapy are shown in Figs. 4c and d, in which each datum was normalized by dividing it by its corresponding baseline.


A decline of LAMP- 2 predicts ursodeoxycholic acid response in primary biliary cirrhosis.

Wang L, Guo GY, Wang JB, Zhou XM, Yang Q, Han ZY, Li Q, Zhang JW, Cai Y, Ren XL, Zhou X, Chen RR, Shi YQ, Han Y, Fan DM - Sci Rep (2015)

The changes of serum LAMP-2 levels in responders and non-responders after 1 year of UDCA treatment.(a, b) The prominent decline in LAMP-2 was noted in the third month in responders. (c, d) The changes of serum LAMP-2 levels in responders and non-responders. Each datum was normalized by dividing it by its corresponding baseline. The biochemical responses were evaluated by Paris Definitions (a and c) or by Barcelona Definitions (b and d). Data are expressed as mean SEM. *p<0.001 versus baseline.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4403591&req=5

f4: The changes of serum LAMP-2 levels in responders and non-responders after 1 year of UDCA treatment.(a, b) The prominent decline in LAMP-2 was noted in the third month in responders. (c, d) The changes of serum LAMP-2 levels in responders and non-responders. Each datum was normalized by dividing it by its corresponding baseline. The biochemical responses were evaluated by Paris Definitions (a and c) or by Barcelona Definitions (b and d). Data are expressed as mean SEM. *p<0.001 versus baseline.
Mentions: Under UDCA therapy, a prominent decline in serum LAMP-2 was noted in the third month in responders, and gradually decreased subsequently, with a maximum decrease observed at the sixth month (Figs. 4a and b, green; p<0.001). However, serum LAMP-2 was decreased slightly in non-responders (Figs. 4a and b, red), even with an elevation at 1 year (Fig. 4b). After 1 year of UDCA treatment, serum LAMP-2 was decreased by about 42% with Paris criteria, and 45% with Barcelona criteria in responders, while in non-responders it was decreased by about 2% with Paris criteria and 10% with Barcelona criteria. The changes of serum LAMP-2 after 1 year of UDCA therapy are shown in Figs. 4c and d, in which each datum was normalized by dividing it by its corresponding baseline.

Bottom Line: We found that the basal serum LAMP-2 level was increased in PBC, especially in patients with stage III-IV (p = 0.010) or TBIL > 1 mg/dL (p = 0.014).Baseline serum LAMP-2 was higher in non-responders than that in responders, but the difference was statistically insignificant.However, after UDCA treatment, serum LAMP-2 level decreased prominently in the first 3 months, which was more obvious in responders.

View Article: PubMed Central - PubMed

Affiliation: Division of Hepatology, Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xian, 710032, Shaanxi Province, China.

ABSTRACT
Biochemical response to ursodeoxycholic acid (UDCA) in patients with primary biliary cirrhosis (PBC) is variable. We have previously reported that augmented expression of lysosome-associated membrane protein 2 (LAMP-2) was correlated with the severity of PBC. This study aimed to determine whether serum LAMP-2 could serve as a predictor of biochemical response to UDCA. The efficiency of serum LAMP-2 to predict biochemical response was assessed after 1 year of UDCA treatment in PBC patients by a retrospective analysis. We found that the basal serum LAMP-2 level was increased in PBC, especially in patients with stage III-IV (p = 0.010) or TBIL > 1 mg/dL (p = 0.014). Baseline serum LAMP-2 was higher in non-responders than that in responders, but the difference was statistically insignificant. However, after UDCA treatment, serum LAMP-2 level decreased prominently in the first 3 months, which was more obvious in responders. Further studies showed that the 35% decline of LAMP-2 after treatment for 3 months could be stated as an indicator of UDCA response with the sensitivity of 62.9% and specificity of 75.0% by Paris criteria. Meanwhile the specificity and sensitivity were identified as 63.5% and 64.1% by Barcelona criteria. Together, a decline in LAMP-2 might help to predict the response to UDCA.

No MeSH data available.


Related in: MedlinePlus